Detailed Information
Cited 3 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
- Authors
- Yoo, C[Yoo, Changhoon]; Ryoo, BY[Ryoo, Baek-Yeol]; Kim, HD[Kim, Hyung-Don]; Ryu, MH[Ryu, Min-Hee]; Kang, B[Kang, Beodeul]; Chon, HJ[Chon, Hong Jae]; Hong, JY[Hong, Jung Yong]; Lim, HY[Lim, Ho Yeong]
- Issue Date
- 1-Feb-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.4
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 4
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.